Mankind Pharma has executed a landmark agreement to acquire a branded generic business for Rs 7.97 billion and signed a Business Transfer Agreement with its wholly-owned subsidiary Bharat Serums & Vaccines (BSV). This strategic move enhances Mankind’s portfolio, boosting its presence in women’s health, fertility, and critical care segments.
Mankind Pharma Limited, a leading Indian pharmaceutical company, has entered into a significant agreement to acquire a branded generic business valued at Rs 7.97 billion. Concurrently, Mankind Pharma has completed a Business Transfer Agreement (BTA) involving its wholly-owned subsidiary Bharat Serums & Vaccines Limited (BSV), further strengthening its product portfolio and market presence in specialty segments.
This acquisition empowers Mankind Pharma to expand its footprint in the women’s health and fertility drug market and gain access to high-entry barrier products in critical care, including complex recombinant and biologic medicines. Bharat Serums & Vaccines, known for its robust R&D capabilities and strong product portfolio, has been instrumental in reinforcing Mankind’s growing leadership in these therapeutic areas.
Mankind Pharma financed these strategic acquisitions through a judicious mix of internal accruals and external debt, demonstrating its focus on sustainable growth balanced with robust financial health. The company is also considering potential equity raises approved by shareholders to manage its debt profile effectively.
Rajeev Juneja, Vice-chairman and Managing Director of Mankind Pharma, expressed enthusiasm about the deal, stating, “The acquisition aligns perfectly with our vision to innovate and expand in complex healthcare segments. BSV’s established portfolio and strong R&D platforms will accelerate our journey towards being a market leader in women’s health, fertility, and critical care.”
The Business Transfer Agreement enables a seamless integration of BSV’s branded generic assets, facilitating operational synergies in manufacturing, supply chain, and distribution channels. Together, these agreements pave the way for enhanced revenue growth, improved profitability, and stronger market competitiveness.
Key Highlights
-
Acquisition of branded generic business valued at Rs 7.97 billion underlines strategic portfolio expansion.
-
Business Transfer Agreement with Bharat Serums & Vaccines Ltd augments specialty portfolio in women’s health and critical care.
-
BSV brings over five decades of expertise with strong R&D capabilities and niche biologics.
-
Deal financed via internal accruals and external debt, maintaining financial discipline.
-
Mankind Pharma aims to scale high-entry barrier products and expand global reach.
-
Strengthened market leadership in Indian women’s health and fertility drug segments.
-
Synergies expected in commercial operations, manufacturing, and distribution for efficient growth.
-
The transaction demonstrates commitment to innovation, product diversification, and sustainable growth.
This milestone marks a significant chapter in Mankind Pharma’s mission to provide affordable, high-quality healthcare solutions while driving innovation in complex therapeutic areas.
Sources: Mankind Pharma official press releases, Business Standard, Economic Times, Pharma Economic Times, FirstWord Pharma
